KR102911673B1 - Eed 억제제로서의 이미다조피리미딘 및 이의 용도 - Google Patents
Eed 억제제로서의 이미다조피리미딘 및 이의 용도Info
- Publication number
- KR102911673B1 KR102911673B1 KR1020227001061A KR20227001061A KR102911673B1 KR 102911673 B1 KR102911673 B1 KR 102911673B1 KR 1020227001061 A KR1020227001061 A KR 1020227001061A KR 20227001061 A KR20227001061 A KR 20227001061A KR 102911673 B1 KR102911673 B1 KR 102911673B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- mmol
- present disclosure
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874606P | 2019-07-16 | 2019-07-16 | |
| US62/874,606 | 2019-07-16 | ||
| US201962944608P | 2019-12-06 | 2019-12-06 | |
| US62/944,608 | 2019-12-06 | ||
| PCT/US2020/042219 WO2021011713A1 (en) | 2019-07-16 | 2020-07-16 | Imidazopyrimidines as eed inhibitors and the use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220035116A KR20220035116A (ko) | 2022-03-21 |
| KR102911673B1 true KR102911673B1 (ko) | 2026-01-13 |
Family
ID=71895298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227001061A Active KR102911673B1 (ko) | 2019-07-16 | 2020-07-16 | Eed 억제제로서의 이미다조피리미딘 및 이의 용도 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12145944B2 (https=) |
| EP (1) | EP3999510A1 (https=) |
| JP (1) | JP7738909B2 (https=) |
| KR (1) | KR102911673B1 (https=) |
| CN (2) | CN114127073B (https=) |
| AU (1) | AU2020315401B2 (https=) |
| BR (1) | BR112022000713A2 (https=) |
| CA (1) | CA3138560A1 (https=) |
| CL (1) | CL2022000093A1 (https=) |
| IL (1) | IL288872B1 (https=) |
| MX (1) | MX2022000550A (https=) |
| PE (1) | PE20220750A1 (https=) |
| PH (1) | PH12021553233A1 (https=) |
| TW (1) | TWI819225B (https=) |
| UA (1) | UA130084C2 (https=) |
| WO (1) | WO2021011713A1 (https=) |
| ZA (1) | ZA202109518B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113636993B (zh) * | 2020-05-11 | 2022-08-19 | 苏州亚盛药业有限公司 | (5-氟-2,3-二氢苯并呋喃-4-基)甲胺或其盐的制备方法及其中间体 |
| CA3203975A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| CN115028631A (zh) * | 2021-03-05 | 2022-09-09 | 中国科学院上海药物研究所 | 三氮唑并嘧啶衍生物、其药物组合物及用途 |
| CN115212311B (zh) * | 2021-04-19 | 2024-08-09 | 苏州亚盛药业有限公司 | 一种药物组合及其用途 |
| TW202312995A (zh) * | 2021-08-11 | 2023-04-01 | 大陸商上海青煜醫藥科技有限公司 | 氮雜芳基化合物、其製備方法及應用 |
| JP2024529118A (ja) * | 2021-08-13 | 2024-08-01 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | 疾患又は障害の治療方法 |
| CN116514814A (zh) * | 2022-01-30 | 2023-08-01 | 苏州亚盛药业有限公司 | 一种大环类化合物或其盐、溶剂合物的结晶形式或无定形形式 |
| CA3258934A1 (en) * | 2022-06-09 | 2023-12-14 | Battelle Memorial Institute | NON-VIRAL ADMINISTRATION OF SMALL MOLECULE THERAPEUTIC AGENTS |
| WO2024251197A1 (zh) | 2023-06-06 | 2024-12-12 | 苏州亚盛药业有限公司 | Eed抑制剂固体分散体、包含其的口服制剂及其制备方法 |
| AU2024353375A1 (en) | 2023-09-29 | 2026-04-09 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025113665A1 (zh) * | 2023-11-30 | 2025-06-05 | 上海海雁医药科技有限公司 | 稠四杂环衍生物及其药物组合物和用途 |
| WO2025122954A1 (en) | 2023-12-08 | 2025-06-12 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017221100A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Imidazopyrimidine compounds useful for the treatment of cancer |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP4965623B2 (ja) | 2009-09-30 | 2012-07-04 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| WO2014022332A1 (en) | 2012-07-31 | 2014-02-06 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| US10344088B2 (en) | 2013-03-15 | 2019-07-09 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
| WO2015036499A1 (en) | 2013-09-11 | 2015-03-19 | Medimmune Limited | Anti-b7-h1 antibodies for treating tumors |
| AU2015225867B2 (en) | 2014-03-07 | 2020-02-06 | University Health Network | Methods and compositions for modifying the immune response |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| UY36462A (es) | 2014-12-23 | 2016-07-29 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos |
| WO2017221092A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| JP7631193B2 (ja) | 2018-10-22 | 2025-02-18 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| CA3142351A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CA3141826A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| BR112022010924A2 (pt) | 2019-12-06 | 2022-09-06 | Vertex Pharma | Tetra-hidrofuranos substituídos como moduladores de canais de sódio |
-
2020
- 2020-07-16 PH PH1/2021/553233A patent/PH12021553233A1/en unknown
- 2020-07-16 BR BR112022000713A patent/BR112022000713A2/pt unknown
- 2020-07-16 EP EP20750129.7A patent/EP3999510A1/en active Pending
- 2020-07-16 KR KR1020227001061A patent/KR102911673B1/ko active Active
- 2020-07-16 TW TW109124012A patent/TWI819225B/zh active
- 2020-07-16 CA CA3138560A patent/CA3138560A1/en active Pending
- 2020-07-16 WO PCT/US2020/042219 patent/WO2021011713A1/en not_active Ceased
- 2020-07-16 MX MX2022000550A patent/MX2022000550A/es unknown
- 2020-07-16 CN CN202080051201.8A patent/CN114127073B/zh active Active
- 2020-07-16 UA UAA202200645A patent/UA130084C2/uk unknown
- 2020-07-16 US US16/971,472 patent/US12145944B2/en active Active
- 2020-07-16 AU AU2020315401A patent/AU2020315401B2/en active Active
- 2020-07-16 CN CN202410735099.3A patent/CN118745185A/zh active Pending
- 2020-07-16 PE PE2022000071A patent/PE20220750A1/es unknown
- 2020-07-16 IL IL288872A patent/IL288872B1/en unknown
- 2020-07-16 JP JP2022502238A patent/JP7738909B2/ja active Active
-
2021
- 2021-11-24 ZA ZA2021/09518A patent/ZA202109518B/en unknown
-
2022
- 2022-01-13 CL CL2022000093A patent/CL2022000093A1/es unknown
-
2024
- 2024-09-17 US US18/887,703 patent/US20250034162A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017221100A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Imidazopyrimidine compounds useful for the treatment of cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202109518B (en) | 2023-10-25 |
| PE20220750A1 (es) | 2022-05-10 |
| CN118745185A (zh) | 2024-10-08 |
| TW202116772A (zh) | 2021-05-01 |
| CL2022000093A1 (es) | 2022-10-28 |
| IL288872B1 (en) | 2026-04-01 |
| EP3999510A1 (en) | 2022-05-25 |
| JP7738909B2 (ja) | 2025-09-16 |
| US20250034162A1 (en) | 2025-01-30 |
| BR112022000713A2 (pt) | 2022-03-22 |
| WO2021011713A8 (en) | 2022-01-06 |
| AU2020315401B2 (en) | 2025-05-22 |
| US12145944B2 (en) | 2024-11-19 |
| US20220227778A1 (en) | 2022-07-21 |
| CN114127073B (zh) | 2024-05-31 |
| IL288872A (en) | 2022-02-01 |
| MX2022000550A (es) | 2022-02-10 |
| KR20220035116A (ko) | 2022-03-21 |
| UA130084C2 (uk) | 2025-11-05 |
| JP2022541436A (ja) | 2022-09-26 |
| CN114127073A (zh) | 2022-03-01 |
| PH12021553233A1 (en) | 2022-09-19 |
| AU2020315401A1 (en) | 2022-02-17 |
| WO2021011713A1 (en) | 2021-01-21 |
| CA3138560A1 (en) | 2021-01-21 |
| TWI819225B (zh) | 2023-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102911673B1 (ko) | Eed 억제제로서의 이미다조피리미딘 및 이의 용도 | |
| JP2022545735A (ja) | セレブロンｅ３リガーゼ阻害剤 | |
| CN115023267A (zh) | 螺环雄激素受体蛋白质降解剂 | |
| CN110914265B (zh) | 作为lsd-1抑制剂的吡咯并[2,3-c]吡啶和相关类似物 | |
| KR20180132125A (ko) | Mdm2 단백질 분해제 | |
| JP2020515571A (ja) | 共有結合性メニン阻害剤としてのピペリジン | |
| WO2022187423A1 (en) | Cereblon ligands | |
| WO2022187419A1 (en) | Small molecule degraders of androgen receptor | |
| WO2022011204A1 (en) | Small molecule androgen receptor protein degraders | |
| KR20250040644A (ko) | Nrf2 단백질 분해제 | |
| RU2836176C2 (ru) | Имидазопиримидины как ингибиторы eed и их применение | |
| HK40062143A (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| HK40062143B (zh) | 作为eed抑制剂的咪唑幷嘧啶和其用途 | |
| WO2025137626A1 (en) | (hetero)aryl and indolinyl nrf2 protein degraders | |
| HK40041770B (en) | Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors | |
| HK40022861A (en) | Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors | |
| HK40022861B (en) | Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors | |
| HK40006048A (en) | Cxcr4 inhibitors and uses thereof | |
| HK40006048B (en) | Cxcr4 inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |